<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04361071</url>
  </required_header>
  <id_info>
    <org_study_id>XuanwuHvas</org_study_id>
    <nct_id>NCT04361071</nct_id>
  </id_info>
  <brief_title>Clinical Study of Stent Versus Direct Atherectomy to Treat Iliac Artery Occlusive Diseases</brief_title>
  <official_title>Clinical Study of Stent Versus Direct Atherectomy to Treat Iliac Artery Occlusive Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized study comparing stent and plaque excision systems in treatment of Iliac
      artery occlusive disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized study comparing stent and plaque excision systems in treatment of Iliac
      artery occlusive disease
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-month Primary Patency Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Primary patency is defined as no significant reduction of flow detectable by Duplex ultrasound through the index lesion and no further clinically driven target vessel revascularization performed in the interim. Significant reduction of flow is binary restenosis defined as the diameter stenosis &gt;50% with a peak systolic velocity ratio &gt;2.4 as measured by Duplex ultrasound.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-month Limb Salvage Rate</measure>
    <time_frame>12 months</time_frame>
    <description>Limb Salvage is defined as the freedom from secondary major amputation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Index Limb Ischemia at 6-month Follow up</measure>
    <time_frame>6 months</time_frame>
    <description>Index Limb Ischemia is defined by Rutherford/Becker Classification categories 3 through 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Index Limb Ischemia at 12-month Follow up</measure>
    <time_frame>12 months</time_frame>
    <description>Index Limb Ischemia is defined by Rutherford/Becker Classification categories 3 through 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Events at 12-month Post Procedure</measure>
    <time_frame>12 months</time_frame>
    <description>Major adverse events included death, index limb ischemia, index limb amputation, clinically driven target lesion revascularization , and significant embolic events, which were defined as causing end-organ damage.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Iliac Artery Occlusion</condition>
  <arm_group>
    <arm_group_label>Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stent group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atherectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atherectomy group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>stent</intervention_name>
    <description>stent</description>
    <arm_group_label>Stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>plaque excision system</intervention_name>
    <description>plaque excision system</description>
    <arm_group_label>Atherectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patients have non thrombotic arteriosclerosis obliterans of the common iliac or
             external iliac arteries

          2. Clinical diagnosis of stenosis or occlusive disease

          3. The patients have unobstructed distal outflow tract

          4. Receiving surgical treatment at the same time

        Exclusion Criteria:

          1. The patients who have previously implanted stent(s) or stent graft(s) in target leg

          2. Life expectancy less than 12 months

          3. Has any planned surgical or endovascular intervention of target vessel 30 days before
             or after index procedure

          4. Thrombophlebitis, uremia, or deep venous thrombus, within past 30 days

          5. Receiving dialysis or immunosuppressant therapy

          6. Recent stroke within past 90 days

          7. Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix®) or
             ticlopidine (Ticlid®), heparin, Nitinol (nickel titanium), contrast agent, that cannot
             be medically managed

          8. Tissue loss due to ischemic disease (Rutherford/Becker category 5 or 6)

          9. Serum creatinine level &gt;/= 2.5 mg/dl at time of screening visit

         10. Known or suspected active infection at the time of the procedure

         11. Bleeding diathesis

         12. Patient is unwilling or unable to comply with procedures specified in the protocol or
             has difficulty or inability to return for follow-up visits as specified by the
             protocol.

         13. Patients are known to be pregnant, incarcerated, mentally incompetent, and/or alcohol
             or drug abuser.

         14. Patients are currently participating in any other investigational drug or medical
             device study that has not completed primary endpoint(s) evaluation or clinically
             interferes with the endpoints from this study or future participation in such studies
             prior to the completion of this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianming Guo, M.D.</last_name>
    <phone>13146369562</phone>
    <email>guojianming1020@icloud.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yongquan Gu, M.D.</last_name>
    <phone>15901598209</phone>
    <email>15901598209@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yongquan Gu</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianming Guo, M.D.</last_name>
      <phone>13146369562</phone>
      <email>guojianming@icloud.com</email>
    </contact>
    <contact_backup>
      <last_name>Yongquan Gu, M.D.</last_name>
      <phone>15901598209</phone>
      <email>15901598209@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>December 27, 2017</study_first_submitted>
  <study_first_submitted_qc>April 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stent</keyword>
  <keyword>atherectomy</keyword>
  <keyword>iliac Artery</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

